• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.

作者信息

Bansal N, Raturi M, Bansal Y

机构信息

Department of Transfusion Medicine, VCSG Government Institute of Medical Science and Research, Srinagar, Uttarakhand, India.

Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant, Dehradun, Uttarakhand, India.

出版信息

Transfus Clin Biol. 2022 May;29(2):161-163. doi: 10.1016/j.tracli.2021.12.006. Epub 2021 Dec 29.

DOI:10.1016/j.tracli.2021.12.006
PMID:34973463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8714679/
Abstract
摘要

相似文献

1
SARS-CoV-2 variants in immunocompromised COVID-19 patients: The underlying causes and the way forward.免疫功能低下的新冠肺炎患者中的新冠病毒2变体：根本原因及未来方向
Transfus Clin Biol. 2022 May;29(2):161-163. doi: 10.1016/j.tracli.2021.12.006. Epub 2021 Dec 29.
2
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
3
Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性单克隆抗体治疗免疫功能低下宿主的持续性2019冠状病毒病（COVID-19）
Clin Infect Dis. 2022 May 3;74(9):1706-1707. doi: 10.1093/cid/ciab868.
4
Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment.免疫功能低下未接种疫苗的 COVID-19 患者接受单克隆抗体治疗后的长期细胞免疫应答。
Front Immunol. 2022 Oct 13;13:980698. doi: 10.3389/fimmu.2022.980698. eCollection 2022.
5
SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.免疫功能低下患者接受抗体单药治疗后的 SARS-CoV-2 变异株。
Emerg Infect Dis. 2021 Oct;27(10):2725-2728. doi: 10.3201/eid2710.211509. Epub 2021 Aug 5.
6
SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients.免疫功能低下患者中SARS-CoV-2的进化与免疫逃逸
N Engl J Med. 2022 Jun 23;386(25):2436-2438. doi: 10.1056/NEJMc2202861. Epub 2022 Jun 8.
7
Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection.两名免疫功能低下的持续性 COVID-19 感染者在抗体治疗后出现刺突突变的演变。
J Med Virol. 2022 Mar;94(3):1241-1245. doi: 10.1002/jmv.27445. Epub 2021 Nov 13.
8
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection.对一名患有长期新冠病毒2型（SARS-CoV-2）感染的免疫功能低下患者的病毒免疫学评估。
Emerg Microbes Infect. 2022 Dec;11(1):786-789. doi: 10.1080/22221751.2022.2045877.
9
Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications.免疫功能低下宿主中 SARS-CoV-2 的长期无症状携带：临床、免疫学和病毒学意义。
J Clin Immunol. 2022 Oct;42(7):1371-1378. doi: 10.1007/s10875-022-01313-6. Epub 2022 Jul 2.
10
The unmet need for COVID-19 treatment in immunocompromised patients.免疫功能低下患者的 COVID-19 治疗需求未得到满足。
BMC Infect Dis. 2022 Dec 12;22(1):930. doi: 10.1186/s12879-022-07918-x.

引用本文的文献

1
Introducing a framework for within-host dynamics and mutations modelling of H5N1 influenza infection in humans.介绍一种用于人类H5N1流感感染的宿主体内动态和突变建模的框架。
J R Soc Interface. 2025 Jul;22(228):20240910. doi: 10.1098/rsif.2024.0910. Epub 2025 Jul 2.
2
An engineered miniACE2 protein secreted by mesenchymal stromal cells effectively neutralizes multiple SARS-CoV- 2 variants in vitro.间充质基质细胞分泌的一种工程化微型ACE2蛋白在体外可有效中和多种新冠病毒变体。
Mol Med. 2025 Apr 23;31(1):151. doi: 10.1186/s10020-025-01190-w.
3
Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.利用 SARS-CoV-2 测序数据鉴定美国全球新发传染病监测计划中的再感染病例。
Emerg Infect Dis. 2024;30(14):53-61. doi: 10.3201/eid3014.240231.
4
Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics.全球最优试验设计和风险分担安排是避免延误机会成本、确保当前或未来大流行中公平、可行和有效全球疫苗研究和实施的关键。
Front Public Health. 2022 Dec 13;10:1085319. doi: 10.3389/fpubh.2022.1085319. eCollection 2022.
5
SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era.德尔塔（B.1.617.2）和奥密克戎（B.1.1.529）变异株流行时期儿童人群中 SARS-CoV-2 感染情况。
Virol J. 2022 Sep 8;19(1):144. doi: 10.1186/s12985-022-01873-4.
6
COVID-19 infection and transmission includes complex sequence diversity.COVID-19 感染和传播包括复杂的序列多样性。
PLoS Genet. 2022 Sep 8;18(9):e1010200. doi: 10.1371/journal.pgen.1010200. eCollection 2022 Sep.
7
Evolution of SARS-CoV-2 in Spain during the First Two Years of the Pandemic: Circulating Variants, Amino Acid Conservation, and Genetic Variability in Structural, Non-Structural, and Accessory Proteins.SARS-CoV-2 在大流行的头两年中在西班牙的进化：流行变异株、结构蛋白、非结构蛋白和辅助蛋白中的氨基酸保守性和遗传变异性。
Int J Mol Sci. 2022 Jun 7;23(12):6394. doi: 10.3390/ijms23126394.

本文引用的文献

1
Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的奥密克戎变异株（B.1.1.529），全球紧急公共卫生警报！
J Med Virol. 2022 Apr;94(4):1255-1256. doi: 10.1002/jmv.27491. Epub 2021 Dec 7.
2
Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case report.一名患有多次新冠病毒疾病复发的免疫功能低下患者的恢复期血浆治疗：病例报告
Respirol Case Rep. 2021 Nov 9;9(12):e0858. doi: 10.1002/rcr2.858. eCollection 2021 Dec.
3
Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants.COVID-19 患者体内 SARS-CoV-2 的宿主内进化是免疫逃逸变异株的来源。
Nat Commun. 2021 Nov 4;12(1):6405. doi: 10.1038/s41467-021-26602-3.
4
Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case report.康复期血浆疗法对免疫功能低下的新冠肺炎患者的疗效：一例报告
Clin Infect Pract. 2021 Nov;12:100096. doi: 10.1016/j.clinpr.2021.100096. Epub 2021 Sep 1.
5
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
6
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies.巴瑞替尼单抗+依替西单抗疗法在患有B细胞恶性肿瘤的COVID-19患者中诱发了SARS-CoV-2免疫逃逸突变和继发性临床恶化。
Ann Oncol. 2021 Nov;32(11):1445-1447. doi: 10.1016/j.annonc.2021.07.015. Epub 2021 Aug 2.
7
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.SARS-CoV-2 在患有非霍奇金淋巴瘤的免疫功能低下患者中的长期进化。
mSphere. 2021 Aug 25;6(4):e0024421. doi: 10.1128/mSphere.00244-21. Epub 2021 Jul 28.
8
The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic.在不断演变的 COVID-19 大流行中，关注的 SARS-CoV-2 变体的起源和潜在未来。
Curr Biol. 2021 Jul 26;31(14):R918-R929. doi: 10.1016/j.cub.2021.06.049. Epub 2021 Jun 23.
9
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19.恢复期血浆疗法与血液系统恶性肿瘤合并 COVID-19 患者生存情况的关联
JAMA Oncol. 2021 Jun 17;7(8):1167-75. doi: 10.1001/jamaoncol.2021.1799.
10
Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.新冠康复者血浆疗法：剖析其在印度失败的因素。
Transfus Clin Biol. 2021 Aug;28(3):296-298. doi: 10.1016/j.tracli.2021.05.009. Epub 2021 Jun 5.